Praxis Precision Medicines, Inc. (PRAX)
PRAXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$332.00
+54.38 (+19.59%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $9.30bn
- P/E
- –
- EPS, last 4 quarters
- $-12.93
- Dividend yield
- –
- Day range
- –
- 52-week range
- $159.74 to $392.70
- Average volume
- 446.7k
- Previous close
- $277.62
Analysts
14 coveringBuy13 buy, 1 hold, 0 sell
Targets a year out average $752.82, +126.8% from here
Earnings
next estimate $-3.68Next report
Sep 2025
+2.6%
Dec 2025
-16.7%
Mar 2026
+10.6%
Jun 2026
+20.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$78.36m | -$97.04m | -$105.86m | -$96.90m |
| Net income | -$73.93m | -$88.91m | -$92.56m | -$83.72m |
News
8 latest- Praxis Precision Medicines, Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory UpdatesFintel · 10 hours ago
- UBS Initiates Coverage of Praxis Precision Medicines with BuyFintel · Oct 16, 2026
- JP Morgan Initiates Coverage of Praxis Precision Medicines at OverweightFintel · Oct 16, 2026
- Notable Monday Option Activity: PSIX, UVE, PRAXBNK Invest · Sep 28, 2026
- Praxis (PRAX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 13, 2026
- 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This YearZacks · Aug 11, 2026
- Show Me The Money: After An 800%+ Gain, PRAX Enters A High-Stakes Stretch RTTNews · Aug 7, 2026
- Praxis Precision Medicines Q2 Earnings Call HighlightsMarketBeat · Aug 7, 2026
The company
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders for small molecules through Cerebrum, and for antisense oligonucleotides (ASOs) through Solidus, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- praxismedicines.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.